Cellestis' tuberculosis diagnostic:
This article was originally published in Clinica
Melbourne, Australia-based Cellestis has received regulatory approval in South Korea for its tuberculosis (TB) diagnostic, QuantiFERON-TB Gold In-Tube. The test is based on the measurement of IFN-gamma secreted from stimulated T cell lymphocytes previously exposed to Mycobacterium tuberculosis infection. The assay involves an overnight culture of whole blood with tuberculin and control antigens, followed by detection of IFN-gamma in a rapid, single-step, sandwich ELISA. The prevalence of TB in Korea has been reported as 135 per 100,000 people, and BCG vaccination is mandatory. Cellestis will market the test in the Korea via its distributor, Woongbee MeDiTech.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.